Lumicef Dosage/Direction for Use

Posology: The recommended dose is 210 mg administered by subcutaneous injection at weeks 0, 1, and 2 followed by 210 mg every 2 weeks.
Plaque Psoriasis and Generalized Pustular Psoriasis: Patients generally achieve a response to treatment with LUMICEF within 12 weeks of treatment initiation. If no response to treatment is achieved within 12 weeks, carefully reconsider whether to continue the treatment protocol with LUMICEF.
Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthristis: Patients generally achieve a response to treatment with LUMICEF within 16 weeks of treatment initiation. If no response to treatment is achieved within 16 weeks, carefully reconsider whether to continue the treatment protocol with LUMICEF.
Special populations: Use in the Elderly: The elderly generally have reduced physiological functions. Observe such patients carefully and be mindful of possible adverse reactions such as infections.
Pediatric population: The safety and efficacy of LUMICEF in children and adolescents below the age of 18 years have not yet been established. No data are available.
Renal and hepatic impairment: LUMICEF has not been studied in these patient populations. No dose recommendations can be made.
Method of administration: The administration of LUMICEF must be initiated by a physician or under the direct supervision of a physician in a medical institution. After proper training in subcutaneous injection technique, patients may self-inject LUMICEF when deemed appropriate by a physician. Patients should be instructed to inject the full amount of LUMICEF.
Use a different site for each injection. Moreover, do not inject areas of the skin that are sensitive or abnormal (scratch, redness, sclerosis, thickness, scaling, or other abnormalities), or sites of psoriasis. (See Special precautions for disposal and other handling under Cautions For Usage.)